Evaluation of the antihistamine effects of olopatadine and levocetirizine during a 24‐h period: A double‐blind, randomized, cross‐over, placebo‐controlled comparison in skin responses induced by histamine iontophoresis
Abstract:The antihistamine effects of olopatadine and levocetirizine, in standard-dose application described in their information (5 mg twice a day for olopatadine; 5 mg once daily for levocetirizine), were examined from 11.5 to 24 h after application. The test was designed in a double-blind, randomized, cross-over, placebo-controlled study of 12 healthy volunteers on histamine-induced flare and wheal response using an iontophoresis technique. The suppressive effect of olopatadine on the wheals induced by a 0.1-mA hist… Show more
“…After manuscript review, two were excluded for being duplicates and 27 were excluded for not being RCTs. This left 181 articles in 27 journals to be included in the review . Of these, 137 studies had parallel‐armed control groups, 42 had placebo control groups, one was a cross‐over design and one used no treatment as the control group.…”
“…After manuscript review, two were excluded for being duplicates and 27 were excluded for not being RCTs. This left 181 articles in 27 journals to be included in the review . Of these, 137 studies had parallel‐armed control groups, 42 had placebo control groups, one was a cross‐over design and one used no treatment as the control group.…”
Levocetirizine has modest sedative effects with a risk ratio of 1.67 when compared with placebo. The sedative effects observed for levocetirizine are not different from other second-generation antihistamines.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.